Skip to content

Zymeworks ZYME Net unrealized gains (losses) on securities still held

Net unrealized gains (losses) on securities still held at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$1.01M-495%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$658K-1,500%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's net unrealized gains (losses) on securities still held.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's net unrealized gains (losses) on securities still held?
Zymeworks (ZYME) reported net unrealized gains (losses) on securities still held of -$486K in Q1 2026.
How has Zymeworks's net unrealized gains (losses) on securities still held changed year-over-year?
Zymeworks's net unrealized gains (losses) on securities still held decreased by 189.0% year-over-year, from $546K to -$486K.
What does net unrealized gains (losses) on securities still held mean?
The net change in the fair value of investment securities still held by the company that has not yet been realized through a sale. This provides insight into the unrealized performance of the company's treasury and investment management strategy.